Neither avelumab or cetuximab are currently approved for NSCLC, but they showed promising activity in clinical trials for PD-L1 high- [6] or EGFR high-expressing NSCLC patients, respectively [7, 8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.